HBIO Insider Trading Activity and SEC Form 4 Filings
HBIO insider trading summary
Over the past 12 months, insiders at Harvard Bioscience Inc (HBIO) reported 3 open-market purchases worth $99K by 3 insiders and no sales on SEC Form 4. Net insider buying was $99K.
Latest HBIO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2026 | Stephen J Denelsky | Director | Buy | $49K (10,000 @ $4.87) |
| Mar 16, 2026 | Mark T Frost | Chief Financial Officer | Buy | $25K (5,000 @ $5.00) |
| Mar 16, 2026 | John D Duke | Chief Executive Officer | Buy | $25K (5,000 @ $5.01) |
| Jun 13, 2024 | James W Green | Chief Executive Officer | Buy | $29K (10,000 @ $2.91) |
| Jun 6, 2024 | James W Green | Chief Executive Officer | Buy | $61K (20,000 @ $3.07) |
| Aug 17, 2023 | James W Green | Chief Executive Officer | Buy | $110K (25,000 @ $4.38) |
| Mar 15, 2023 | James W Green | Chief Executive Officer | Buy | $52K (20,000 @ $2.60) |
| Mar 15, 2023 | Alan I Edrick | Director | Buy | $42K (16,192 @ $2.62) |
| Mar 14, 2023 | Alan I Edrick | Director | Buy | $37K (13,808 @ $2.67) |
| Mar 14, 2023 | James W Green | Chief Executive Officer | Buy | $53K (20,000 @ $2.67) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.